Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Harte Hanks (HHS) EBIAT (2016 - 2025)

Harte Hanks has reported EBIAT over the past 16 years, most recently at $2.2 million for Q4 2025.

  • Quarterly EBIAT rose 190.47% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$811000.0 through Dec 2025, up 97.32% year-over-year, with the annual reading at -$811000.0 for FY2025, 97.32% up from the prior year.
  • EBIAT was $2.2 million for Q4 2025 at Harte Hanks, up from -$2.3 million in the prior quarter.
  • Over five years, EBIAT peaked at $21.8 million in Q4 2022 and troughed at -$27.8 million in Q2 2024.
  • The 5-year median for EBIAT is $361000.0 (2023), against an average of $953450.0.
  • Year-over-year, EBIAT skyrocketed 1141.69% in 2022 and then crashed 4898.97% in 2024.
  • A 5-year view of EBIAT shows it stood at $1.8 million in 2021, then skyrocketed by 1141.69% to $21.8 million in 2022, then plummeted by 109.07% to -$2.0 million in 2023, then decreased by 23.12% to -$2.4 million in 2024, then soared by 190.47% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for HHS's EBIAT are $2.2 million (Q4 2025), -$2.3 million (Q3 2025), and -$335000.0 (Q2 2025).